

## 1 **Robust metabolomic age prediction based on a wide selection of metabolites**

2 Key words: metabolomics, ridge regression, prediction, aging, xenobiotics

3 Tariq Faquih<sup>1</sup>, Astrid van Hylckama Vlieg<sup>1</sup>, Praveen Surendran<sup>2,3,4,5,6</sup>, Adam S. Butterworth<sup>2,3,4,7,8</sup>,  
4 Ruifang Li-Gao<sup>1,9</sup>, Renée de Mutsert<sup>1</sup>, Frits R. Rosendaal<sup>1</sup>, Raymond Noordam<sup>10</sup>, Diana van Heemst<sup>10</sup>,  
5 Ko Willems van Dijk<sup>11,12,13</sup>, Dennis O. Mook-Kanamori<sup>1,14</sup>

6 <sup>1</sup> Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands;  
7 [T.O.Faquih@lumc.nl](mailto:T.O.Faquih@lumc.nl) (T.O.F.); (A.v.H.V.); (R.L.-G.); (R.d.M); (F.R.R.);  
8 (D.O.M.-K.)

9 <sup>2</sup> British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary  
10 Care, University of Cambridge, Cambridge, UK; (P.S.)

11 <sup>3</sup> British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK;  
12 (P.S.)

13 <sup>4</sup> Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,  
14 Cambridge, UK; (P.S.)

15 <sup>5</sup> Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge,  
16 Cambridge, UK; (P.S.)

17 <sup>6</sup> GSK plc., Stevenage, England, United Kingdom

18 <sup>7</sup> Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.

19 <sup>8</sup> NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, Department of Public  
20 Health and Primary Care, University of Cambridge, Cambridge, UK.

21 <sup>9</sup> Metabolon, Inc., Morrisville, North Carolina, United State of America; (R.L.-G.)

22 <sup>10</sup> Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical  
23 Center, Leiden, The Netherlands; (R.N.); (D.v.H.)

24 <sup>11</sup> Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands;  
25 (K.W.v.D)

26 <sup>12</sup> Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center,  
27 Leiden, The Netherlands; (K.W.v.D)

28 <sup>13</sup> Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center,  
29 Leiden, The Netherlands; (K.W.v.D)

30 <sup>14</sup> Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The  
31 Netherlands; (D.O.M.-K.)

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 32 **Abstract**

33 Chronological age is a major risk factor for numerous diseases. However, chronological age does not  
34 capture the complex biological aging process. Biological aging can occur at a different pace in  
35 individuals of the same chronological age. Therefore, the difference between the chronological age  
36 and biologically driven aging could be more informative in reflecting health status. Metabolite levels  
37 are thought to reflect the integrated effects of both genetic and environmental factors on the rate of  
38 aging, and may thus provide a stronger signature for biological age than those previously developed  
39 using methylation and proteomics. Here, we set out to develop a metabolomic age prediction model  
40 by applying ridge regression and bootstrapping with 826 metabolites (of which 678 endogenous and  
41 148 xenobiotics) measured by an untargeted high-performance liquid chromatography mass  
42 spectrometry platform (Metabolon) in 11,977 individuals (50.2% men) from the INTERVAL study  
43 (Cambridge, UK). Participants of the INTERVAL study are relatively healthy blood donors aged 18-75  
44 years. After internal validation using bootstrapping, the models demonstrated high performance with  
45 an adjusted  $R^2$  of 0.82 using the endogenous metabolites only and an adjusted  $R^2$  of 0.83 when using  
46 the full set of 826 metabolites with age as outcome. The latter model performance could be indicative  
47 of xenobiotics predicting frailty. In summary, we developed robust models for predicting metabolomic  
48 age in a large relatively healthy population with a wide age range.

## 49 **Introduction**

50 Chronological age is a major risk factor for a multitude of diseases (1, 2). The biology of aging  
51 comprises complex and multifactorial processes that are influenced by genetic, lifestyle and  
52 environmental factors (3-5). Evidently, the rate of biological aging varies between individuals, as in  
53 contrast to other individuals of the same age group, wherein, some individuals are able to live to an  
54 older chronological age without age-related diseases and disability (3). This suggests that  
55 chronological age does not align with the biological aging process. For this reason, several studies have  
56 aimed to capture the signature of biological changes due to aging process by predicting its rate based  
57 on biological factors using, for example, DNA methylation (6) and proteins (7).

58 Metabolomic profiling aims to identify small molecules that are mostly substrates or products of  
59 metabolism (metabolites). The number of metabolomics studies has increased in recent years due to  
60 major technological advances and the availability of (validated and high throughput) commercial and  
61 noncommercial analyses platforms. In addition, the current platforms have improved their capability  
62 to detect and quantify large numbers of endogenous and xenobiotic metabolites(8, 9). Since individual  
63 metabolomic profiles reflect the influences of both genetic and acquired factors, they are thought to  
64 provide a more holistic representation of biological processes, such as aging (8, 9). Furthermore, as

65 metabolomic profiles are strongly affected by chronological age (4, 10) and sex (11, 12), they have  
66 been used to develop prediction models of chronological age (i.e., the metabolomic age) (13-16).  
67 However, predicting metabolomic age using metabolomics had limited success or faced  
68 methodological limitations due to several reasons. First, some studies used a relatively small sample  
69 size to predict age using hundreds or even thousands of metabolite predictors (10, 17). The inclusion  
70 of a larger number of predictors than the number of samples may cause overfitting and bias. Second,  
71 previous metabolomic age studies used targeted platforms, such as the Nightingale platform, that  
72 specifically measure a small number of lipoproteins and some low-molecular metabolites. This limits  
73 the variety of the metabolites and the information used for the prediction of age. Third, studies may  
74 be limited by the age distribution of the cohort study. This may restrict the model to a specific age  
75 range which affects the generalizability of the model in other studies and other age groups (10).  
76 Fourth, generalizability may also be reduced if the model is developed in cohorts with an oversampling  
77 of individuals with specific disease outcomes or specific population characteristics (7, 13). Fifth,  
78 statistical methodology such as stepwise selection, have been reported to cause overfitting of the  
79 prediction model (18). Finally, it is challenging to examine the model's validity and generalizability in  
80 external studies or different populations particularly due to the dynamic nature of metabolite levels  
81 (19-21).

82 In this study, we aimed to develop a model to predict metabolomic age in a large healthy population  
83 with a widespread age range, using a single untargeted metabolomics platform. To attain this goal,  
84 we developed a prediction model using data from the INTERVAL study (22) (University of Cambridge,  
85 Cambridge, UK). Metabolomic profiles were available in 11,977 participants as measured using  
86 Metabolon's (Durham, North Carolina, USA) untargeted metabolomics platform. These  
87 measurements included a broad range of endogenous and xenobiotic metabolites (n=1,363) from  
88 various biochemical pathways, thereby enabling the capture of metabolites related to a vast range of  
89 ageing effects.

## 90 **Methods**

### 91 **INTERVAL Study**

92 The INTERVAL study is a prospective cohort study of approximately 50,000 participants nested within  
93 a pragmatic randomized sample of blood donors (22). Between 2012 and 2014, blood donors, aged  
94 18 years and older, were consented and recruited from 25 National Health Service Blood and  
95 Transplant (NHSBT) static donor centers across the UK. The INTERVAL study was approved by The  
96 National Research Ethics Service (11/EE/0538). Individuals with major disease (myocardial infarction,

97 stroke, cancer etc.) as well as those who reported being unwell or having had recent illness or infection  
98 or did not fulfill the other criteria required for blood donation (22, 23) were ineligible for the study.  
99 Therefore, participants included in the study were predominantly healthy. Participants completed  
100 online questionnaires addressing basic lifestyle and health-related information, including self-  
101 reported height and weight, ethnicity, smoking status, alcohol consumption, doctor-diagnosed  
102 anemia, use of medications (hormone replacement therapy, iron supplements) and menopausal  
103 status (22). Untargeted metabolomic data were available in 11,979 individuals (age range 18 - 75).  
104 Two individuals had incorrect or missing height/weight values and were therefore excluded from the  
105 study. Thus, the final sample size for the current study was 11,977.

### 106 **Untargeted metabolomic measurements**

107 Untargeted metabolomic measurements were quantified at Metabolon Inc. (Durham, North Carolina,  
108 USA) using Metabolon™ Discovery HD4 platform. In brief, this process involves four independent ultra-  
109 high-performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (24, 25). Of  
110 these platforms, two used positive ionization reverse phase chromatography, one used negative  
111 ionization reverse phase chromatography, and one used hydrophilic interaction liquid  
112 chromatography negative ionization (25). Known metabolites were annotated at Metabolon Inc. with  
113 chemical names, super pathways, sub pathways, biochemical properties, and compound identifiers  
114 from various metabolite databases. Metabolomic measurements in the INTERVAL study were  
115 conducted in three batches (n=4087, 4566, and 3326). Subsequent harmonization and quality checks  
116 were performed between the batches by Metabolon. All metabolite measurements were scaled to a  
117 median of 1.

### 118 **Selection of Predictors**

119 We aimed to select metabolites consistently and reliably measured by the Metabolon platform. In  
120 total 1,411 metabolites were measured in the INTERVAL study. First, we removed metabolites  
121 completely missing in at least one of the batches (n=175). Second, we excluded metabolites without  
122 annotation (unnamed metabolites) (n=258), keeping only endogenous and xenobiotic metabolites.  
123 These metabolites were excluded as they are inconsistently measured by the platform and are highly  
124 variable between batches and studies. Moreover, the lack of full annotation increases the uncertainty  
125 that we are using the same metabolite across batches and studies and leaves no secondary  
126 information for further verification. Third, we excluded metabolites measured in less than 100  
127 individuals (n=30). Fourth, to ensure that the metabolites that are used for our model are not unique  
128 for the INTERVAL study, we cross-referenced our dataset with an independent study with Metabolon

129 measurements. For this we used the Netherlands Epidemiology of Obesity (NEO) study, a population-  
130 based (n=599) cohort study of individuals aged 45–65 years (26, 27). Based on this comparison, we  
131 additionally excluded 122 metabolites that were not detected in the NEO study. The final set of  
132 metabolites included 826 metabolites, with 678 endogenous and 148 xenobiotic metabolites that  
133 were confirmed to be regularly measured by the Metabolon platform (Figure 1).

#### 134 **Missing value imputation**

135 Missing values were imputed using the pipeline as described in our previous work (27). In brief,  
136 endogenous metabolites were imputed by multiple imputation using chained equations method to  
137 generate five imputed datasets (m=5). For each metabolite with missing values, we used the outcome  
138 variable (i.e., age), 5-10 highly correlated related metabolites, body mass index (BMI), center number  
139 where the blood samples were collected, and the batch number to impute the missing values.  
140 Xenobiotic metabolites were imputed to zero to account for true missingness.

#### 141 **Model Development**

142 For the development of the model, we used ridge regression (28) to reduce potential overfitting. Cross  
143 validation was performed (n=10) in each imputed dataset to calculate the optimal shrinkage term  
144 ( $\lambda$ ). Subsequently the mean of the  $\lambda$  values was used to develop the model on the stacked  
145 imputed datasets (i.e., all 5 datasets combined as one). Accordingly, the weight of the observations in  
146 the stacked dataset was set to  $1/m = 1/5 = 0.2$  (20). As the outcome (age) is a continuous variable, we  
147 assessed the fit of the model by deriving the  $R^2$ . As an additional sensitivity test, we used generalized  
148 additive model (GAM) to examine and calculate the  $R^2$  for the nonlinear correlation. Internal validation  
149 was performed using bootstrapping (b=100). Bootstrapping results were used for the optimization of  
150  $R^2$  and the calculation of the mean squared error (MSE) and the mean absolute error (MAE) of the  
151 model. Two models were developed using two sets of the selected metabolite predictors. First, we  
152 used the full set of endogenous and xenobiotic metabolites (n=826) to develop “model A”. Second,  
153 we used only the endogenous metabolites (n=678) to develop “model B”. As previous studies found  
154 that metabolomic profiles (12, 29) and aging (30-32) are influenced by the sex of individuals, we  
155 included sex as an additional predictor in both models.

#### 156 **Sample size considerations**

157 The primary database used to create the prediction model was the INTERVAL study (n= 11,977) with  
158 826 predictors. We used the formulas described by Riley et al. (33) to confirm that our sample size (n)  
159 and number of predictor (p) are sufficient to minimize overfitting and provide high prediction  
160 precision. First, we calculated Copas global shrinkage factor for our data (34, 35) to see if it is above

161 the recommended 0.9 threshold (33). Based on this calculation the estimated shrinkage factor was  
162 0.95 if the adjusted  $R^2$  of the model was assumed to be 0.7. Second, we calculated the sample size  
163 required to ensure a small difference between the  $R^2$  and the adjusted  $R^2$  for the development model.  
164 Assuming the adjusted  $R^2$  was 0.7 again and a small desired  $R^2$  difference ( $R^2_{diff}=0.025$ ), then the  
165 sample size required to achieve this should be at least  $n=9913$ . Third, we checked the sample size  
166 required for precise residual standard deviation of the model. Accordingly, we found the multiplicative  
167 margin of error (MMOE) to be less than 10% (MMOE =1.3%) using our  $n$  and  $p$  in the INTERVAL study.  
168 Finally, we checked the precision of the mean predicted outcome value (predicted age) of the model.  
169 We used  $n$  and  $p$  for the INTERVAL study and assumed that predicted age would have a mean of 45  
170 and a variance of 35. Accordingly, the upper and lower bounds were approximately 45.34 and 44.65  
171 respectively. Thus, the MMOE for the mean predicted outcome was less 1% (MMOE=  $45.34 / 45 =$   
172  $1.007 = 0.7\%$ ). Therefore, the sample size of the INTERVAL study was optimal to minimize overfitting,  
173 optimism, and provide a precise estimation of the residual standard deviation and mean predicted  
174 values.

175 **Results**

176 **Population characteristics**

177 Characteristics of the total INTERVAL study population and age subgroups are summarized in Table 1.  
178 In total 11,977 individuals were included and had a normal age distribution with a mean age of 45  
179 years and a range of 18 – 75 years. The number of men and women was approximately equal (50.2%  
180 were men). BMI was largely in the recommended range of 18.5-24.9 kg/m<sup>2</sup> (36) with a mean BMI of  
181 22.8 kg/m<sup>2</sup> and was similar in all age groups.

182


	Total	18 to 25	25 to 35	35 to 45	45 to 55	55 to 65	65 to 75
N	11977	1178	2245	2152	2867	2602	811
Age (years), mean (range)	45 (18-75)						
Men, n (%)	6019 (50.2%)	485 (41.2%)	965 (42.3%)	1042 (48.4%)	1560 (54.4%)	1480 (56.9%)	546 (67.3%)
BMI (kg/m <sup>2</sup> ), mean (SD)	22.8 (4.2)	21.3 (4.0)	22.0 (4.2)	23.3 (4.4)	23.5 (4.3)	23.0 (3.9)	22.6 (3.5)

183 Table 1. Characteristics of the INTERVAL study population.

184 **Metabolomic Age Prediction**

185 Prediction models A (endogenous plus xenobiotic metabolites) and B (endogenous metabolites only)  
186 were developed in the INTERVAL study using ridge regression. The workflow including metabolite  
187 selection, missing value imputation, and analyses are summarized in Figure 1. Internal validation using  
188 bootstrapping (resampling n = 100) and optimization provided an R<sup>2</sup> of 0.83 (MSE=31, MAE=4.4) for  
189 model A, and 0.82 (MSE=33.7, MAE=4.6) for model B. The R<sup>2</sup> for the generalized additional model  
190 (GAM) were slightly higher for both models, 0.85 for model A and 0.84 for model B (Figure 2,  
191 Supplementary Table 1, Supplementary Figure 1). Full tables with the intercept, sex and metabolite  
192 coefficients for model A and B are provided in Supplementary Table 2. This table also contains the  
193 mean values for the metabolites from the INTERVAL study.

194




195

196

197

Figure 1: Flowchart of the selection of predictor metabolites and the development steps for the metabolomic age prediction model in the INTERVAL study





198

199 Figure 2: Correlation plots of the Metabolomic age (predicted age) on the horizontal axis and the  
200 chronological age on the vertical axis for model A (A) and model B (B). The data used is the stacked  
201 imputed datasets in the INTERVAL study. Abbreviations: GAM, generalized additive model.

## 202 Discussion

203 In this study, we developed a prediction model for metabolomic age based on metabolite  
204 measurements, including a wide range of endogenous and xenobiotic metabolites belonging to a  
205 variety of biochemical pathways. The metabolomic measurements were performed in a single study  
206 using the same metabolomic platform and harmonized for within study and between batch variation.  
207 Importantly, we used multiple imputation, ridge regression, and bootstrapping (20) to develop and  
208 internally validate the metabolomic age prediction models. We developed two models, with the first  
209 model A using both endogenous and xenobiotic metabolites (n=826), and the second model B using  
210 the endogenous metabolites only (n=678). Both models had high adjusted  $R^2$  (model A = 0.83; Model  
211 B = 0.82), however, model B had slightly higher MSE and MAE, indicating higher error for the predicted  
212 values.

## 213 Ridge Regression for Metabolomic Age

214 Our metabolomic age model is based on ridge regression which generates shrinkage factors that  
215 shrink metabolite coefficients with weak influence on the model to small values. Unlike methods such  
216 as LASSO and elastic net regression, this shrinkage never causes the coefficients to reach zero.  
217 Therefore, unlike those methods, ridge regression does not perform selection of predictors, in this  
218 case metabolites, due to the shrinkage term. Thus, the model consistently includes the same  
219 metabolites during the cross validation and internal validation by bootstrapping (20). Ridge regression

220 thus ensures rigorousness and consideration of all the selected metabolite predictors. In addition, we  
221 found in our model that nonlinear GAM  $R^2$  to be slightly higher than linear  $R^2$  in both models. Figure 2  
222 also shows that the GAM line curves at the edges of the age ranges. Therefore, predicting  
223 metabolomic age from this model in a nonlinear form, by adding a quadratic term or using a spline  
224 function, may further expand the model flexibility.

## 225 **Strengths and Limitations**

226 A major strength of our current study is the development of robust metabolomic age prediction  
227 models based on a large number of metabolites measured in a large cohort with a wide age  
228 distribution. This sample size was confirmed to fit the required criteria for developing a model with  
229 low overfitting (33). Furthermore, the INTERVAL study included relatively healthy blood donors as  
230 participants. Blood donors are prescreened for a number of common diseases, making it a suitable  
231 study to develop a metabolomic age without being affected by specific disease-related effects on  
232 metabolites. Unlike previous metabolomic age predictors (alternatively referred to as metabolomic  
233 “clocks”), we developed our model using the latest Metabolon metabolomics platform that measures  
234 a large selection of metabolites. An advantage of this platform is the inclusion of xenobiotics, such as  
235 those derived from medication or pollution as well as endogenous metabolites. Thus, we were able to  
236 include metabolites originating from various internal and external sources. The xenobiotic metabolites  
237 represent some of the acquired environmental and lifestyle exposures of individuals that could play a  
238 role in biological aging. For example, medication metabolites could be a predictor of frailty. However,  
239 our study has two limitations. First, because the INTERVAL study does not have data for health-related  
240 outcomes, we could not assess the effects of different disease outcomes and health phenotypes on  
241 the metabolomic age. Second, as the INTERVAL study used here was cross sectional, we could not  
242 examine the model overtime or examine the ability of metabolomic age to predict disease outcomes  
243 or mortality in a future time point.

## 244 **External Validation for Metabolomic Age and Future Applications**

245 Prediction models may suffer from overfitting due to selection bias, small sample size, methodology  
246 limitations, and lack of internal validation and calibration during development. However, another  
247 common issue regarding prediction modelling, such as the case with metabolomic age, is the challenge  
248 to externally validate them. This a common issue with prediction models in general. Indeed, few  
249 studies perform external validation of prediction models (19, 37). The reasons for the lack of external  
250 validation include the difficulty of applying and reproducing the prediction model method, lack of the  
251 full prediction variables to develop the model in the new dataset, or a lack of an appropriate sample

252 size for external validation. Without external validation, the quality of the models cannot be properly  
253 assessed, and a model could still be overfitted despite presenting good results during internal  
254 validation(20, 21, 38). We took advantage of the sample size and wide age range to use a stringent  
255 ridge regression and internal validation method to develop the metabolomic age model. The resulting  
256 model demonstrated a high  $R^2$  for the metabolomic age. The high  $R^2$  from our models is unlikely to be  
257 due be overfitting as we considered and calculated the power and sensitivity of the model based on  
258 the sample size and number predictors (33), in addition to the rigorous prediction modelling  
259 methodology. The metabolomic age was able to predict chronological age well but not perfectly. The  
260 missing 0.2 from  $R^2$  is likely a reflection the biological aging process captured by the metabolomic age.  
261 However, future robust external validation, using weak and moderate calibrations in other  
262 populations (38) would be valuable for the metabolomic age models presented in this paper.

263 Several age prediction models have been developed that utilize different biological measurements  
264 such as targeted metabolomics (7, 14), proteomics (7), and epigenetics (DNA methylation)(6). These  
265 studies have reported that the metabolites were a strong predictor of body mass index, metabolic  
266 syndrome, cancer (7), type 2 diabetes, and cardiovascular disease (14). Furthermore, other biological  
267 clocks using proteomics and epigenetics were reported to be associated with depression and other  
268 outcomes (7). Therefore, it will be valuable to apply the prediction models presented in this paper in  
269 large longitudinal cohorts and examine the metabolomic age in relation to calendar age with the  
270 aforementioned phenotypes and other health related outcomes. Assessing the association between  
271 the residual between the chronological and metabolomic age with disease and health phenotypes  
272 overtime will provide clinically relevant prediction. The prediction strength will indicate the  
273 robustness of our model and provide the means to for external validation and re-calibration of the  
274 model.

275 In addition to our aim of addressing primary issues of the development of metabolomic age models,  
276 the Metabolon platform is expanded on the range of metabolites that can potentially be a better  
277 predictor of age. For example, previous metabolomic age studies have not measured or included  
278 xenobiotic metabolites. In our study, we were able to include this additional group of metabolites in  
279 model A. Furthermore, Model A may also be used in tandem with metabolomic age from targeted  
280 platforms, and biological clocks of different biological molecules measurements, similar to the work  
281 by Jansen et al. (7), to possibly improve or compare their predictive performance and their ability of  
282 capturing the effects of health-related phenotypes.

## 283 **Conclusions**

284 We developed metabolomic age prediction models in a large relatively healthy population using a  
285 wide array of endogenous and xenobiotic metabolites. In model A with the endogenous and  
286 xenobiotic metabolites and in model B with endogenous metabolites only, the  $R^2$  of the linear fit was  
287 0.82 and 0.83, respectively. We provided the full list of metabolites and their coefficients for both  
288 models. This data can enable other researchers to replicate our metabolomic age prediction model,  
289 externally validate it in their own studies with different disease outcomes and combine them with  
290 other age prediction models.

## 291 References

- 292 1. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. *Circ Res.*  
293 2012;110(8):1097-108. doi:10.1161/CIRCRESAHA.111.246876
- 294 2. Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the role of  
295 concussive and subconcussive impacts. 2012;40(3):138.
- 296 3. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.*  
297 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039
- 298 4. Hoffman JM, Lyu Y, Pletcher SD, Promislow DEL. Proteomics and metabolomics in ageing  
299 research: from biomarkers to systems biology. *Essays Biochem.* 2017;61(3):379-88.  
300 doi:10.1042/EBC20160083
- 301 5. Brooks-Wilson AR. Genetics of healthy aging and longevity. 2013;132(12):1323-38.
- 302 6. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biology.*  
303 2013;14(10):3156. doi:10.1186/gb-2013-14-10-r115
- 304 7. Jansen R, Han LK, Verhoeven JE, et al. An integrative study of five biological clocks in somatic  
305 and mental health. *Elife.* 2021;10. doi:10.7554/eLife.59479
- 306 8. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art  
307 in 2015. *Front Bioeng Biotechnol.* 2015;3:23. doi:10.3389/fbioe.2015.00023
- 308 9. Rattray NJW, Deziel NC, Wallach JD, et al. Beyond genomics: understanding exposotypes  
309 through metabolomics. *Hum Genomics.* 2018;12(1):4. doi:10.1186/s40246-018-0134-x
- 310 10. Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. *Nature Reviews*  
311 *Genetics.* 2022. doi:10.1038/s41576-022-00511-7
- 312 11. Martin FJ, Montoliu I, Kussmann M. Metabonomics of ageing - Towards understanding  
313 metabolism of a long and healthy life. *Mech Ageing Dev.* 2017;165(Pt B):171-9.  
314 doi:10.1016/j.mad.2016.12.009
- 315 12. Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. *Aging*  
316 *Cell.* 2012;11(6):960-7. doi:10.1111/j.1474-9726.2012.00865.x
- 317 13. Macdonald-Dunlop E, Taba N, Klarić L, et al. A catalogue of omics biological ageing clocks  
318 reveals substantial commonality and associations with disease risk. *Aging.* 2022;14(2):623-59.  
319 doi:10.18632/aging.203847
- 320 14. van den Akker EB, Trompet S, Barkey Wolf JJH, et al. Metabolic Age Based on the BBMRI-NL  
321 (1)H-NMR Metabolomics Repository as Biomarker of Age-related Disease. *Circulation. Genomic and*  
322 *precision medicine.* 2020;13(5):541-7. doi:10.1161/circgen.119.002610
- 323 15. Hertel J, Friedrich N, Wittfeld K, et al. Measuring Biological Age via Metabonomics: The  
324 Metabolic Age Score. *J Proteome Res.* 2016;15(2):400-10. doi:10.1021/acs.jproteome.5b00561
- 325 16. Rist MJ, Roth A, Frommherz L, et al. Metabolite patterns predicting sex and age in  
326 participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. *PLoS One.*  
327 2017;12(8):e0183228. doi:10.1371/journal.pone.0183228
- 328 17. Hwangbo N, Zhang X, Raftery D, et al. A Metabolomic Aging Clock Using Human  
329 Cerebrospinal Fluid. *The Journals of Gerontology: Series A.* 2021;77(4):744-54.  
330 doi:10.1093/gerona/glab212 %J The Journals of Gerontology: Series A
- 331 18. Smith G. Step away from stepwise. *Journal of Big Data.* 2018;5(1):32. doi:10.1186/s40537-  
332 018-0143-6
- 333 19. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic  
334 models: what, why, how, when and where? *Clinical Kidney Journal.* 2020;14(1):49-58.  
335 doi:10.1093/ckj/sfaa188 %J Clinical Kidney Journal
- 336 20. Steyerberg EW. *Clinical Prediction Models.* 2nd ed. Cham, Switzerland: Springer  
337 International Publishing; 2019.
- 338 21. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction  
339 research:: A clinical example. *Journal of Clinical Epidemiology.* 2003;56(9):826-32.  
340 doi:[https://doi.org/10.1016/S0895-4356\(03\)00207-5](https://doi.org/10.1016/S0895-4356(03)00207-5)

- 341 22. Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals  
342 between blood donations can be safely and acceptably decreased to optimise blood supply: study  
343 protocol for a randomised controlled trial. *Trials*. 2014;15:363-. doi:10.1186/1745-6215-15-363  
344 23. NHS Blood Donation Who can give blood. 2022. [https://www.blood.co.uk/who-can-give-](https://www.blood.co.uk/who-can-give-blood)  
345 [blood](https://www.blood.co.uk/who-can-give-blood).  
346 24. Evans A, Bridgewater B, Liu Q, et al. High resolution mass spectrometry improves data  
347 quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput  
348 profiling metabolomics. 2014;4(2):1.  
349 25. Rhee EP, Waikar SS, Rebholz CM, et al. Variability of Two Metabolomic Platforms in CKD.  
350 *Clinical Journal of the American Society of Nephrology*. 2019;14(1):40. doi:10.2215/CJN.07070618  
351 26. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity  
352 (NEO) study: study design and data collection. *Eur J Epidemiol*. 2013;28(6):513-23.  
353 doi:10.1007/s10654-013-9801-3  
354 27. Faquih T, van Smeden M, Luo J, et al. A Workflow for Missing Values Imputation of  
355 Untargeted Metabolomics Data. *Metabolites*. 2020;10(12). doi:10.3390/metabo10120486  
356 28. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal Problems.  
357 *Technometrics*. 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634  
358 29. Saner C, Harcourt BE, Pandey A, et al. Sex and puberty-related differences in metabolomic  
359 profiles associated with adiposity measures in youth with obesity. *Metabolomics*. 2019;15(5):75.  
360 doi:10.1007/s11306-019-1537-y  
361 30. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. *eLife*.  
362 2021;10:e63425. doi:10.7554/eLife.63425  
363 31. Nakamura E, Miyao K, JoGSABS, Sciences M. Sex differences in human biological aging.  
364 2008;63(9):936-44.  
365 32. McCrory C, Fiorito G, McLoughlin S, et al. Epigenetic clocks and allostatic load reveal  
366 potential sex-specific drivers of biological aging. 2020;75(3):495-503.  
367 33. Riley RD, Snell KIE, Ensor J, et al. Minimum sample size for developing a multivariable  
368 prediction model: Part I - Continuous outcomes. *Statistics in medicine*. 2019;38(7):1262-75.  
369 doi:10.1002/sim.7993  
370 34. Copas JB. Regression, prediction and shrinkage. *Journal of the Royal Statistical Society: Series*  
371 *B*. 1983;45(3):311-35.  
372 35. Copas JB. Using regression models for prediction: shrinkage and regression to the mean.  
373 *Statistical methods in medical research*. 1997;6(2):167-83. doi:10.1177/096228029700600206  
374 36. WHO WHO. A healthy lifestyle - WHO recommendations. World Health Organization: WHO.  
375 2010.  
376 37. Siontis GCM, Tzoulaki I, Castaldi PJ, Ioannidis JPA. External validation of new risk prediction  
377 models is infrequent and reveals worse prognostic discrimination. *Journal of Clinical Epidemiology*.  
378 2015;68(1):25-34. doi:<https://doi.org/10.1016/j.jclinepi.2014.09.007>  
379 38. Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive  
380 analytics. *BMC Medicine*. 2019;17(1):230. doi:10.1186/s12916-019-1466-7

381

382

### 383 Funding

384 The INTERVAL study was funded by NHSBT and the NIHR Blood and Transplant Research Unit in  
385 Donor Health and Genomics (NIHR BTRU-2014-10024). The trial's coordinating centre at the  
386 Department of Public Health and Primary Care at the University of Cambridge, Cambridge, UK, has  
387 received core support from the UK Medical Research Council (G0800270), British Heart Foundation  
388 (SP/09/002), and the NIHR Cambridge Biomedical Research Centre. Investigators at the University of  
389 Oxford, Oxford, UK, have been supported by the Research and Development Programme of NHSBT,  
390 the NHSBT Howard Ostin Trust Fund, and the NIHR Oxford Biomedical Research Centre through the  
391 programme grant NIHR-RP-PG-0310-1004. We thank the blood donors who participated in the trial  
392 and NHSBT's operational staff.

393 The NEO study is supported by the participating Departments, the Division, and the Board of  
394 Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile  
395 Area 'Vascular and Regenerative Medicine'. The analyses of metabolites are funded by the VENI  
396 grant (ZonMW-VENI Grant 916.14.023) of D.O.M.-K., D.v.H. and R.N. were supported by a grant of  
397 the VELUX Stiftung [grant number 1156]. T.O.F. was supported by the King Abdullah Scholarship  
398 Program and King Faisal Specialist Hospital & Research Center [No. 1012879283].

### 399 Conflicts of Interest

400 P.S. is an associate director of applied and statistical genetics at GlaxoSmithKline plc. A.S.B. reports  
401 institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and  
402 Sanofi. R.L.-G. is a part-time clinical research consultant for Metabolon, Inc. All other co- authors  
403 have no conflicts of interest to declare.

### 404 Acknowledgments and Disclosures

405 The authors of the NEO study thank all participants, all participating general practitioners for inviting  
406 eligible participants, all research nurses for data collection, and the NEO study group: Pat van  
407 Beelen, Petra Noordijk, and Ingeborg de Jonge for coordination, laboratory, and data management.  
408 The NEO study was approved by the medical ethical committee of the Leiden University Medical  
409 Centre (LUMC) and all participants provided written informed consent.

### 410 Author Contributions

411 T.O.F.- conceptualization, data curation, formal analysis, investigation, methodology, software,  
412 visualization, writing-original draft. P.S. – supervision, conceptualization, project administration,  
413 resources, funding acquisition, writing – review & editing. A.S.B – project administration, resources,  
414 funding acquisition, writing – review & editing. R.L.-G.- validation, writing – review & editing. R.d.M.-  
415 project administration, resources, funding acquisition, writing – review & editing. R.N. and D.V.H.-  
416 funding acquisition, writing – review & editing. F.R.R.- funding acquisition. A.v.H.V. and K.W.v.D-  
417 conceptualization, supervision, writing – review & editing. D.O.M.-K.- conceptualization, supervision,  
418 funding acquisition, writing – review & editing.